Prevalence and Antimicrobial Profile of Colonized ‎Enterococcus Species Isolated from Hospitalized and Non-hospitalized Patients, Khartoum, Sudan

Loai A Siddig^1, , Omnia M Hamid¹, Nasreldin Elhadi² and Magdi A Bayoumi³

¹Microbiology Department, Faculty of Medical Laboratory Sciences, University of Medical Sciences and ‎Technology (UMST), Khartoum, Sudan

²Department of Clinical Laboratory Science, College of Applied Medical Sciences, Imam Abdulrahman ‎Bin Faisal University, Dammam, Kingdom of Saudi Arabia

³‎3Microbiology Department, Faculty of Medicine, University of Medical Sciences and Technology (UMST), ‎Khartoum, Sudan

Cite this paper:
Loai A Siddig, Omnia M Hamid, Nasreldin Elhadi and Magdi A Bayoumi. Prevalence and Antimicrobial Profile of Colonized ‎Enterococcus Species Isolated from Hospitalized and Non-hospitalized Patients, Khartoum, Sudan. American Journal of Infectious Diseases and Microbiology. 2022; 10(4):119-125. doi: 10.12691/ajidm-10-4-1

Abstract

Objective: in this study, we evaluate the prevalence, antimicrobial profiles, and vancomycin resistance (van) genotype ‎of fecal Enterococcus isolates from hospitalized and non-hospitalized patients in Khartoum locality hospitals, Sudan. ‎Methodology: This is a cross-sectional study, conducted between Oct 2018 and March 2020 at four tertiary hospitals in the ‎Khartoum locality. A total number of 588 fecal samples were collected and processed using microbiological culture media ‎‎ (Bile Esculin agar), gram stain, and gram-positive biochemical set tests to identify Enterococci species. Antibiogram of ‎Enterococci strains was performed, and the disk diffusion method of Kirby-Bauer has been used with the broth microdilution‎ method for vancomycin ‎minimum inhibitory concentration. A multiplex polymerase chain reaction assay was used to provide simultaneous identification at ‎the species level and detection of vancomycin resistance (van) genotypes characterization.‎ Results: All tested enterococci were confirmed to the species level, van genes were detected, and the MIC values determined vancomycin. Overall, Enterococcal species were isolated from 170/588 (28.9%) of the study subjects. Among the ‎Enterococcus isolates, 70 (41.2%) were isolated from hospitalized patients, and 100 (58.8%) were isolated from non-hospitalized patients. The isolates were E. faecium 108 (63.5%), followed by E. faecalis 43 (25.3%) ‎and 19 (11.2%) other Enterococcus spp. Enterococcus isolates show overall high resistance to ceftazidime (80.0%), ‎followed by amoxicillin-clavulanic acid (70%), gentamycin (69.4%), and erythromycin (52.4%). A higher ‎prevalence of resistance to ampicillin, rifampin, and teicoplanin was detected in E. faecium than that in E. faecalis and ‎other Enterococcus spp., while a greater prevalence of resistance to ceftazidime, and ciprofloxacin was ‎found in E. faecalis. ‎Twenty-five (14.7%) strains of fecal Enterococci were found to be vancomycin resistant with vanA 19 (11.2%), vanB 5 ‎‎(2.9%), and 1 (0.6%) vanC1 genotypes. The most predominant van producer strains were E. faecium [18, 16.7%; vanA (n= ‎‎17) & vanB (n= 1)] followed by E. faecalis [6, 14.0%; vanA (n= 2), and vanB (n= 4)] and Other Enterococcus spp. [1, 5.3%; ‎vanC1 (n= 1)].‎ Conclusion: The present study provides the first comprehensive report ‎of the ‎antimicrobial ‎resistance pattern ‎ and shows Khartoum localities are repositories for the vancomycin resistance ‎Enterococcus with vanA, vanB, and vanC1 genotypes in human feces of both hospitalized and non-hospitalized patients. ‎It is imperative to track and implement infection control measures in both settings to prevent the spread of these strains.‎

Keywords:
fecal enterococci vancomycin-resistant enterococci van genotypes Khartoum Sudan

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	T. J. G. Teresita, P. Phu and and S. H. R. Willems, V. Willem, W. Mark, P. van, “Characterization of Enterococcus Isolates Colonizing the Intestinal Tract of Intensive Care Unit Patients Receiving Selective Digestive Decontamination,” Front. Microbiol., vol. 8, p. 1596, 2017.
[2]	K. C. Ndubuisi, J.C., Olonitola, O.S., Olayinka, A.T., Jatau, E.D. & Iregbu, “Prevalence and antibiotics susceptibility profile of enterococcus spp. isolated from some hospitals in Abuja, Nigeria.,” African J. Clin. Exp. Microbiol., vol. 18, no. 3, pp. 154-158, 2017.
[3]	S. Gordon, J. Swenson, B.Hill, N. Pigott, R. Facklam, R Cooksey, C. Thornsberry, “Antimicrobial susceptibility patterns of common and unusual species of enterococci causing infections in the United States. Enterococcal Study Group.,” J. Clin. Microbiol., vol. 30, no. 9, pp. 2373-2378, Sep. 1992.
[4]	K. Dubin and E. G. Pamer, “Enterococci and Their Interactions with the Intestinal Microbiome,” Microbiol. Spectr., vol. 5, no. 6, Dec. 2014.
[5]	U. V. John and J. Carvalho, “Enterococcus: Review of its physiology, pathogenesis, diseases and the challenges it poses for clinical microbiology,” Front. Biol. (Beijing)., vol. 6, no. 5, pp. 357-366, Oct. 2011.
[6]	T. Kenzaka, N. Takamura, A. Kumabe, and K. Takeda, “A case of subacute infective endocarditis and blood access infection caused by Enterococcus durans.,” BMC Infect. Dis., vol. 13, p. 594, Dec. 2013.
[7]	A. H. A. M. van Hoek, D. Mevius, B. Guerra, P. Mullany, A. P. Roberts, and H. J. M. Aarts, “Acquired Antibiotic Resistance Genes: An Overview,” Front. Microbiol., p. 203, 2011.
[8]	J. Akhter, S. Ahmed, A. A. Saleh, and S. Anwar, “Antimicrobial resistance and in vitro biofilm-forming ability of Enterococci spp. isolated from urinary tract infection in a tertiary care hospital in Dhaka.,” Bangladesh Med. Res. Counc. Bull., vol. 40, no. 1, pp. 6-9, Apr. 2014.
[9]	M. M. Huycke, D. F. Sahm, and M. S. Gilmore, “Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future,” Emerg. Infect. Dis., vol. 4, no. 2, pp. 239-249, 1998.
[10]	J. J. Wade, “Enterococcus faecium in hospitals,” Eur. J. Clin. Microbiol. Infect. Dis., vol. 16, no. 2, pp. 113-119, 1997.
[11]	WHO Regional Office for Europe/European Centre for Disease Prevention and Control., “Antimicrobial resistance surveillance in Europe 2022-2020 data,” Copenhagen: WHO Regional Office for Europe; 2022, 2022.
[12]	C. Horner, S. Mushtaq, M. Allen, R. Hope, S. Gerver, C. Longshaw, R. Reynolds, N. Woodford, D. Livermore, “Replacement of Enterococcus faecalis by Enterococcus faecium as the predominant enterococcus in UK bacteraemias,” JAC Antimicrob Resist, 2021.
[13]	R. R. Facklam and M. D. Collins, “Identification of Enterococcus species isolated from human infections by a conventional test scheme,” J. Clin. Microbiol., vol. 27, no. 4, 1989.
[14]	C. R. Jackson, P. J. Fedorka-Cray, and J. B. Barrett, “Use of a genus- and species-specific multiplex PCR for identification of enterococci,” J. Clin. Microbiol., vol. 42, no. 8, pp. 3558-3565, Aug. 2004.
[15]	X. Pérez-Hernández, S. Méndez-Álvarez, and F. Claverie-Martín, “A PCR assay for rapid detection of vancomycin-resistant enterococci,” Diagn. Microbiol. Infect. Dis., vol. 42, no. 4, pp. 273-277, 2002.
[16]	A. W. Bauer, W. M. Kirby, J. C. Sherris, and M. Turck, “Antibiotic susceptibility testing by a standardized single disk method.,” Am. J. Clin. Pathol., vol. 45, no. 4, pp. 493-496, Apr. 1966.
[17]	Clinical and Laboratory Standards Institute (CLSI)., “Performance Standards for Antimicrobial Susceptibility Testing. 31st ed. M100-Ed31,” USA, 2021.
[18]	H. Endtz, N. Van Den, A. Van Belkum, J. Kluytmans, J. Koeleman, L. Spanjaard, A. Voss, A. Weersink, C. Vandenbroucke-Grauls, A. Buiting, A. Van Duin, H. Verbrugh “Fecal carriage of vancomycin-resistant enterococci in hospitalized patients and those living in the community in The Netherlands.,” J. Clin. Microbiol., vol. 35, no. 12, p. 3026, 1997.
[19]	N. Hijazi, A. A. Elmanama, and A. Al-Hindi, “Vancomycin-resistant enterococci in fecal samples from hospitalized patients and non-hospitalized individuals in Gaza City,” J. Public Health (Bangkok)., vol. 17, no. 4, pp. 243-249, Aug. 2009.
[20]	Y. Tian, H. Yu, and Z. Wang, “Distribution of acquired antibiotic resistance genes among Enterococcus spp. isolated from a hospital in Baotou, China,” BMC Res. Notes, vol. 12, no. 27, 2019.
[21]	P. Cui, L. Feng, L. Zhang, J. He, T. An, X. Fu, C. Li, X. Zhao, Y. Zhai, H. Li, W. Yan, H. Li, X. Luo, C. Lei, H. Wang, X. Yang, “Antimicrobial Resistance, Virulence Genes, and Biofilm Formation Capacity Among Enterococcus species From Yaks in Aba Tibetan Autonomous Prefecture, China,” Front. Microbiol., vol. 11, p. 1250, Jun. 2020.
[22]	S. Hay, P. Rao, C. Dolecek, N. Day, A. Stergachis, A. Lopez, C. Murray, “Measuring and mapping the global burden of antimicrobial resistance,” BMC Med., vol. 16, no. 1, pp. 1-3, Jun. 2018.
[23]	Federal Ministry of Health, “Republic of Sudan Federal Ministry of Health & Ministry of Animal Resources National Action plan on Antimicrobial Resistance,” Khartoum, 2018.
[24]	A. Abamecha, B. Wondafrash, and A. Abdissa, “Antimicrobial resistance profile of Enterococcus species isolated from intestinal tracts of hospitalized patients in Jimma, Ethiopia,” BMC Res. Notes, vol. 8, p. 213, 2015.
[25]	C. J. Kristich, L. B. Rice, and C. A. Arias, “Enterococcal Infection—Treatment and Antibiotic Resistance.,” in Enterococci: From Commensals to Leading Causes of Drug Resistant Infection, M. S. Gilmore, D. B. Clewell, Y. Ike, and N. Shankar, Eds. Boston, 2014.
[26]	P. Gagetti, L. Bonofiglio, G. García Gabarrot, S. Kaufman, K. Mollerach, L. Vigliarolo, M. von Specht, I. Toresani, H. Lopardo, “Resistance to β-lactams in enterococci" Rev. Argent. Microbiol., vol. 51, no. 2, pp. 179-183, 2019.
[27]	CLSI supplement M100., “Performance Standards for Antimicrobial Susceptibility Testing. 28th ed.,” CLSI, vol. 38, no. 3, p. 15, 2018.
[28]	R. Zaheer, S. Cook, R. Barbieri, N. Goji, A. Cameron, A. Petkau, R. Polo, L. Tymensen, C. Stamm, J. Song, S. Hannon, T. Jones, D. Church, C. Booker, K. Amoako, G. Van Domselaar, R. Read, T. McAllister, “Author Correction: Surveillance of Enterococcus spp. reveals distinct species and antimicrobial resistance diversity across a One-Health continuum,” Sci. Rep., vol. 10, no. 1, Dec. 2020.
[29]	R. E. Mendes, M. Castanheira, D. J. Farrell, R. K. Flamm, H. S. Sader, and R. N. Jones, “Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency,” J. Antimicrob. Chemother., vol. 71, no. 12, pp. 3453-3458, Dec. 2016.
[30]	M. Treskova, A. Kuhlmann, F. Freise, L. Kreienbrock, and S. Brogden, “Occurrence of Antimicrobial Resistance in the Environment in Germany, Austria, and Switzerland: A Narrative Review of Existing Evidence,” Microorganisms, vol. 10, no. 4, Apr. 2022.
[31]	WHO, Criticall Important Antimicrobials for Human Medicine, 6th rev. Geneva, Switzerland, 2019.
[32]	L.Wang, Y. Zhang, S. Liu, N. Huang, W. Zeng, W. Xu, T. Zhou, M. Shen, “Comparison of anti-microbic and anti-biofilm activity among tedizolid and radezolid against linezolid-resistant enterococcus faecalis isolates,” Infect. Drug Resist., vol. 14, no. August, pp. 4619-4627, 2021.
[33]	A. Tedim, P. Ruiz-Garbajosa, J. Corander, C. Rodríguez, R. Cantón, R. Willems, F. Baquero, T. Coque “Population biology of intestinal Enterococcus Isolates from hospitalized and nonhospitalized individuals in different age groups,” Appl. Environ. Microbiol., vol. 81, no. 5, pp. 1820-1831, 2015.
[34]	Y. Adebisi, N. Jimoh, I. Ogunkola, T. Uwizeyimana, A. Olayemi, N. Ukor, D. Lucero-Prisno “The use of antibiotics in COVID-19 management: a rapid review of national treatment guidelines in 10 African countries,” Trop. Med. Health, vol. 49, no. 1, Dec. 2021.
[35]	A. Karna, R. Baral, and B. Khanal, “Characterization of Clinical Isolates of Enterococci with Special Reference to Glycopeptide Susceptibility at a Tertiary Care Center of Eastern Nepal,” Int. J. Microbiol., p. 8, 2019.
[36]	L. Puchter, I. F. Chaberny, F. Schwab, R. P. Vonberg, F. C. Bange, and E. Ebadi, “Economic burden of nosocomial infections caused by vancomycin-resistant enterococci,” Antimicrob. Resist. Infect. Control, vol. 7, no. 1, 2018.
[37]	A. Moghimbeigi, M. Moghimbeygi, M. Dousti, F. ‎Kiani, Faezeh F. Sayehmiri, N. Sadeghifard, A. ‎Nazari,‎ “Prevalence of vancomycin resistance among isolates of enterococci in Iran: a systematic review and meta-analysis,” Adolesc. Health. Med. Ther., vol. 9, pp. 177-188, Nov. 2018.
[38]	O. Ayobami, N. Willrich, A. Reuss, T. Eckmanns, and R. Markwart, “The ongoing challenge of vancomycin-resistant Enterococcus faecium and Enterococcus faecalis in Europe: an epidemiological analysis of bloodstream infections,” Emerg. Microbes Infect., vol. 9, 2020.
[39]	J. Yang, D. Lee, Y. Kim, B. Kang, K. Kim, and N. Ha, “Occurrence of the van genes in Enterococcus faecalis and Enterococcus faecium from clinical isolates in Korea,” Arch. Pharm. Res., vol. 30, no. 3, pp. 329-336, Mar. 2007.
[40]	N. Khandelwal, T. Panwala, J. S. Patel, A. Professor, and J. Research Fellow, “Prevalence of enterococcus species and its vancomycin ‎resistance pattern in a tertiary care hospital, surat, gujarat, ‎india: a growing threat,” Int. J. Recent Sci. Res., vol. 11, no. 7, pp. 39342-39344, 2020.
[41]	A. Melese, C. Genet, and T. Andualem, “Prevalence of Vancomycin resistant enterococci (VRE) in Ethiopia: A systematic review and meta-analysis,” BMC Infect. Dis., vol. 20, no. 1, 2020.
[42]	A. A. Elmanama, “Vancomycin Resistant Enterococci (VRE) among Non–Hospitalized Individuals in Gaza City, Palestine,” J. Al Azhar Univ. (Natural Sci., vol. 10, pp. 31-40, 2008.
[43]	A. Vasilakopoulou, P. Karakosta, S. Vourli, A. Tarpatzi, P. Varda, M. Kostoula, A. Antoniadou, and S. Pournaras, “Gastrointestinal Carriage of Vancomycin-Resistant Enterococci and Carbapenem-Resistant Gram-Negative Bacteria in an Endemic Setting: Prevalence, Risk Factors, and Outcomes,” Front. Public Heal., vol. 8, p. 55, Mar. 2020.
[44]	Y.-B. Se, H.-J. Chun, H.-J. Yi, D.-W. Kim, Y. Ko, and S.-J. Oh, “Incidence and Risk Factors of Infection Caused by Vancomycin-Resistant Enterococcus Colonization in Neurosurgical Intensive Care Unit Patients,” J Korean Neurosurg Soc, vol. 46, no. 2, pp. 123-129, 2009.
[45]	C. L. Correa-Martínez, A. Jurke, J. Schmitz, F. Schaumburg, S. Kampmeier, and A. Mellmann, “Molecular Epidemiology of Vancomycin-Resistant Enterococci Bloodstream Infections in Germany: A Population-Based Prospective Longitudinal Study,” Microorganisms, vol. 10, no. 1, 2022.
[46]	W. Matthew L. Faron, a Nathan A. Ledeboer,a, “Resistance Mechanisms, Epidemiology, and Approaches to Screening for Vancomycin-Resistant Enterococcus in the Health Care Setting,” J Clin Microbiol., vol. 54, no. 10, pp. 2436-2447, 2016.
[47]	J. Bell, J. Paton, and J. Turnidge, “Emergence of vancomycin-resistant enterococci in Australia: phenotypic and genotypic characteristics of isolates,” J. Clin. Microbiol., vol. 36, no. 8, pp. 2187-2190, 1998.
[48]	H. L. Sun, C. Liu, J. J. Zhang, Y. M. Zhou, and Y. C. Xu, “Molecular characterization of vancomycin-resistant enterococci isolated from a hospital in Beijing, China,” J. Microbiol. Immunol. Infect., vol. 52, no. 3, 2019.
[49]	G. Purohit, R. Gaind, R. Dawar, P. Verma, K. Aggarwal, R. Sardana, M. Deb “Characterization of Vancomycin Resistant Enterococci in Hospitalized Patients and Role of Gut Colonization,” J. Clin. Diagn. Res., vol. 11, no. 9, p. DC01, Sep. 2017.
[50]	J. H. Jorgensen, S. A. Crawford, C. C. Kelly, and J. E. Patterson, “In vitro activity of daptomycin against vancomycin-resistant enterococci of various Van types and comparison of susceptibility testing methods,” Antimicrob. Agents Chemother., vol. 47, no. 12, pp. 3760-3763, Dec. 2003.